Determination of carnitine levels in plasma: importance in the study of patients with neuromuscular diseases.
Autor(a) principal: | |
---|---|
Data de Publicação: | 2002 |
Outros Autores: | |
Tipo de documento: | Artigo |
Idioma: | por |
Título da fonte: | Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
Texto Completo: | https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/1913 |
Resumo: | L-carnitine plays a major role in the transport of the long chain fatty acids for the beta-oxidation in the mitochondria. The deficiency of the carnitine is associated by the deficit of the beta-oxidation of the long chain fatty acids and so a different syndromes. The purpose of this study was to determine the plasmatic concentrations of the carnitine and its metabolites in patients with neuromuscular pathologies within the group of mitochondrial myopathies by the comparison with a control group. The study comprised 11 healthy volunteers and 11 patients with neuromuscular mitochondrial diseases. The plasmatic concentrations of the free carnitine, total carnitine and the short and long chain acilcarnitine were determined by using the radio enzymatic method with Acetyl Co A 14C. The values were calculated by the standard curve in increased concentrations of the L-carnitine in aquous solution. RESULTS: The values were expressed as mean +/- S.D. The control group gave the following values: For free carnitine (32.6 +/- 4.95 microM), total carnitine (38.48 +/- 5.8 microM), short chain acylcarnitine (4.12 +/- 0.95 microM) and for long chain acylcarnitine (1.73 +/- 0.15 microM). The patients were divided in two groups according to their values: The 1st group gave the values within the control group: For free carnitine (31.44 +/- 3.72 microM), total carnitine (36.6 +/- 3.86 microM), short chain acylcarnitine (3.52 +/- 1.56 microM) and long chain acylcarnitine (1.68 +/- 0.08 microM). The 2nd group gave values bellow the control group: For free carnitine (16.8 +/- 6.3 microM), total carnitine (20.88 +/- 6.26 microM), short chain acylcarnitine (2.98 +/- 0.81 microM) and long chain acylcarnitine (0.92 +/- 0.41 microM) respectively. In conclusion, this method showed appropriate and accurate for the determinations of the carnitine and its metabolites in plasma, and must be useful for clinical support. |
id |
RCAP_a211b7001468dd563d786fdcb85e0c1d |
---|---|
oai_identifier_str |
oai:ojs.www.actamedicaportuguesa.com:article/1913 |
network_acronym_str |
RCAP |
network_name_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository_id_str |
7160 |
spelling |
Determination of carnitine levels in plasma: importance in the study of patients with neuromuscular diseases.Determinação dos níveis da carnitina no plasma sua importância no estudo em doentes com doenças neuromusculares.L-carnitine plays a major role in the transport of the long chain fatty acids for the beta-oxidation in the mitochondria. The deficiency of the carnitine is associated by the deficit of the beta-oxidation of the long chain fatty acids and so a different syndromes. The purpose of this study was to determine the plasmatic concentrations of the carnitine and its metabolites in patients with neuromuscular pathologies within the group of mitochondrial myopathies by the comparison with a control group. The study comprised 11 healthy volunteers and 11 patients with neuromuscular mitochondrial diseases. The plasmatic concentrations of the free carnitine, total carnitine and the short and long chain acilcarnitine were determined by using the radio enzymatic method with Acetyl Co A 14C. The values were calculated by the standard curve in increased concentrations of the L-carnitine in aquous solution. RESULTS: The values were expressed as mean +/- S.D. The control group gave the following values: For free carnitine (32.6 +/- 4.95 microM), total carnitine (38.48 +/- 5.8 microM), short chain acylcarnitine (4.12 +/- 0.95 microM) and for long chain acylcarnitine (1.73 +/- 0.15 microM). The patients were divided in two groups according to their values: The 1st group gave the values within the control group: For free carnitine (31.44 +/- 3.72 microM), total carnitine (36.6 +/- 3.86 microM), short chain acylcarnitine (3.52 +/- 1.56 microM) and long chain acylcarnitine (1.68 +/- 0.08 microM). The 2nd group gave values bellow the control group: For free carnitine (16.8 +/- 6.3 microM), total carnitine (20.88 +/- 6.26 microM), short chain acylcarnitine (2.98 +/- 0.81 microM) and long chain acylcarnitine (0.92 +/- 0.41 microM) respectively. In conclusion, this method showed appropriate and accurate for the determinations of the carnitine and its metabolites in plasma, and must be useful for clinical support.L-carnitine plays a major role in the transport of the long chain fatty acids for the beta-oxidation in the mitochondria. The deficiency of the carnitine is associated by the deficit of the beta-oxidation of the long chain fatty acids and so a different syndromes. The purpose of this study was to determine the plasmatic concentrations of the carnitine and its metabolites in patients with neuromuscular pathologies within the group of mitochondrial myopathies by the comparison with a control group. The study comprised 11 healthy volunteers and 11 patients with neuromuscular mitochondrial diseases. The plasmatic concentrations of the free carnitine, total carnitine and the short and long chain acilcarnitine were determined by using the radio enzymatic method with Acetyl Co A 14C. The values were calculated by the standard curve in increased concentrations of the L-carnitine in aquous solution. RESULTS: The values were expressed as mean +/- S.D. The control group gave the following values: For free carnitine (32.6 +/- 4.95 microM), total carnitine (38.48 +/- 5.8 microM), short chain acylcarnitine (4.12 +/- 0.95 microM) and for long chain acylcarnitine (1.73 +/- 0.15 microM). The patients were divided in two groups according to their values: The 1st group gave the values within the control group: For free carnitine (31.44 +/- 3.72 microM), total carnitine (36.6 +/- 3.86 microM), short chain acylcarnitine (3.52 +/- 1.56 microM) and long chain acylcarnitine (1.68 +/- 0.08 microM). The 2nd group gave values bellow the control group: For free carnitine (16.8 +/- 6.3 microM), total carnitine (20.88 +/- 6.26 microM), short chain acylcarnitine (2.98 +/- 0.81 microM) and long chain acylcarnitine (0.92 +/- 0.41 microM) respectively. In conclusion, this method showed appropriate and accurate for the determinations of the carnitine and its metabolites in plasma, and must be useful for clinical support.Ordem dos Médicos2002-02-27info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttps://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/1913oai:ojs.www.actamedicaportuguesa.com:article/1913Acta Médica Portuguesa; Vol. 15 No. 1 (2002): Janeiro-Fevereiro; 11-15Acta Médica Portuguesa; Vol. 15 N.º 1 (2002): Janeiro-Fevereiro; 11-151646-07580870-399Xreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAPporhttps://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/1913https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/1913/1481Siqueira, Maria CíntiaMorgado, Fernandoinfo:eu-repo/semantics/openAccess2022-12-20T10:59:30Zoai:ojs.www.actamedicaportuguesa.com:article/1913Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T16:17:28.673086Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse |
dc.title.none.fl_str_mv |
Determination of carnitine levels in plasma: importance in the study of patients with neuromuscular diseases. Determinação dos níveis da carnitina no plasma sua importância no estudo em doentes com doenças neuromusculares. |
title |
Determination of carnitine levels in plasma: importance in the study of patients with neuromuscular diseases. |
spellingShingle |
Determination of carnitine levels in plasma: importance in the study of patients with neuromuscular diseases. Siqueira, Maria Cíntia |
title_short |
Determination of carnitine levels in plasma: importance in the study of patients with neuromuscular diseases. |
title_full |
Determination of carnitine levels in plasma: importance in the study of patients with neuromuscular diseases. |
title_fullStr |
Determination of carnitine levels in plasma: importance in the study of patients with neuromuscular diseases. |
title_full_unstemmed |
Determination of carnitine levels in plasma: importance in the study of patients with neuromuscular diseases. |
title_sort |
Determination of carnitine levels in plasma: importance in the study of patients with neuromuscular diseases. |
author |
Siqueira, Maria Cíntia |
author_facet |
Siqueira, Maria Cíntia Morgado, Fernando |
author_role |
author |
author2 |
Morgado, Fernando |
author2_role |
author |
dc.contributor.author.fl_str_mv |
Siqueira, Maria Cíntia Morgado, Fernando |
description |
L-carnitine plays a major role in the transport of the long chain fatty acids for the beta-oxidation in the mitochondria. The deficiency of the carnitine is associated by the deficit of the beta-oxidation of the long chain fatty acids and so a different syndromes. The purpose of this study was to determine the plasmatic concentrations of the carnitine and its metabolites in patients with neuromuscular pathologies within the group of mitochondrial myopathies by the comparison with a control group. The study comprised 11 healthy volunteers and 11 patients with neuromuscular mitochondrial diseases. The plasmatic concentrations of the free carnitine, total carnitine and the short and long chain acilcarnitine were determined by using the radio enzymatic method with Acetyl Co A 14C. The values were calculated by the standard curve in increased concentrations of the L-carnitine in aquous solution. RESULTS: The values were expressed as mean +/- S.D. The control group gave the following values: For free carnitine (32.6 +/- 4.95 microM), total carnitine (38.48 +/- 5.8 microM), short chain acylcarnitine (4.12 +/- 0.95 microM) and for long chain acylcarnitine (1.73 +/- 0.15 microM). The patients were divided in two groups according to their values: The 1st group gave the values within the control group: For free carnitine (31.44 +/- 3.72 microM), total carnitine (36.6 +/- 3.86 microM), short chain acylcarnitine (3.52 +/- 1.56 microM) and long chain acylcarnitine (1.68 +/- 0.08 microM). The 2nd group gave values bellow the control group: For free carnitine (16.8 +/- 6.3 microM), total carnitine (20.88 +/- 6.26 microM), short chain acylcarnitine (2.98 +/- 0.81 microM) and long chain acylcarnitine (0.92 +/- 0.41 microM) respectively. In conclusion, this method showed appropriate and accurate for the determinations of the carnitine and its metabolites in plasma, and must be useful for clinical support. |
publishDate |
2002 |
dc.date.none.fl_str_mv |
2002-02-27 |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/1913 oai:ojs.www.actamedicaportuguesa.com:article/1913 |
url |
https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/1913 |
identifier_str_mv |
oai:ojs.www.actamedicaportuguesa.com:article/1913 |
dc.language.iso.fl_str_mv |
por |
language |
por |
dc.relation.none.fl_str_mv |
https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/1913 https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/1913/1481 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
Ordem dos Médicos |
publisher.none.fl_str_mv |
Ordem dos Médicos |
dc.source.none.fl_str_mv |
Acta Médica Portuguesa; Vol. 15 No. 1 (2002): Janeiro-Fevereiro; 11-15 Acta Médica Portuguesa; Vol. 15 N.º 1 (2002): Janeiro-Fevereiro; 11-15 1646-0758 0870-399X reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação instacron:RCAAP |
instname_str |
Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
instacron_str |
RCAAP |
institution |
RCAAP |
reponame_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
collection |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository.name.fl_str_mv |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
repository.mail.fl_str_mv |
|
_version_ |
1799130627808690176 |